Benitec Net Income vs Net Income Per Share Analysis
| BNTC Stock | USD 9.85 0.30 2.96% |
Benitec Biopharma financial indicator trend analysis is way more than just evaluating Benitec Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Benitec Biopharma is a good investment. Please check the relationship between Benitec Biopharma Net Income and its Net Income Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Net Income vs Net Income Per Share
Net Income vs Net Income Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Benitec Biopharma Net Income account and Net Income Per Share. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Benitec Biopharma's Net Income and Net Income Per Share is -0.32. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Net Income Per Share in the same time period over historical financial statements of Benitec Biopharma Ltd, assuming nothing else is changed. The correlation between historical values of Benitec Biopharma's Net Income and Net Income Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Benitec Biopharma Ltd are associated (or correlated) with its Net Income Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income Per Share has no effect on the direction of Net Income i.e., Benitec Biopharma's Net Income and Net Income Per Share go up and down completely randomly.
Correlation Coefficient | -0.32 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Benitec Biopharma financial statement analysis. It represents the amount of money remaining after all of Benitec Biopharma Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Net Income Per Share
Most indicators from Benitec Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Benitec Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Benitec Biopharma's Issuance Of Capital Stock is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.99, whereas Sales General And Administrative To Revenue is forecasted to decline to 30.27.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 17.9M | 19.2M | 22.4M | 13.5M | Cost Of Revenue | 9K | 381K | 108K | 202.0K |
Benitec Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Benitec Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Benitec Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 11.6M | 21.4M | 6.0M | 4.5M | 52.2M | 54.8M | |
| Other Current Liab | 662K | 882K | 1.9M | 2.6M | 3.3M | 3.5M | |
| Total Current Liabilities | 1.1M | 1.4M | 2.5M | 4.0M | 4.9M | 5.2M | |
| Total Stockholder Equity | 10.2M | 20.0M | 2.9M | 202K | 47.2M | 49.6M | |
| Property Plant And Equipment Net | 769K | 577K | 993K | 613K | 449K | 517.7K | |
| Net Debt | (9.4M) | (19.6M) | (3.3M) | (1.9M) | (50.6M) | (48.1M) | |
| Retained Earnings | (116.6M) | (130.1M) | (148.3M) | (167.9M) | (190.3M) | (199.8M) | |
| Accounts Payable | 282K | 274K | 422K | 1.1M | 1.4M | 801.4K | |
| Cash | 9.8M | 19.8M | 4.1M | 2.5M | 50.9M | 53.4M | |
| Non Current Assets Total | 778K | 771K | 1.2M | 735K | 536K | 583.5K | |
| Cash And Short Term Investments | 9.8M | 19.8M | 4.1M | 2.5M | 50.9M | 53.4M | |
| Net Receivables | 59K | 25K | 3K | 55K | 229K | 217.6K | |
| Common Stock Shares Outstanding | 60.1K | 252.7K | 480.7K | 1.4M | 4.1M | 4.3M | |
| Liabilities And Stockholders Equity | 11.6M | 21.4M | 6.0M | 4.5M | 52.2M | 54.8M | |
| Inventory | 1.0 | 948K | 1.8 | 13K | 63K | 59.9K | |
| Other Current Assets | 1K | 814K | 755K | 1.3M | 579K | 480.1K | |
| Other Stockholder Equity | 128.8M | 151.6M | 152.5M | 168.9M | 238.4M | 250.3M | |
| Total Liab | 1.3M | 1.4M | 3.1M | 4.3M | 5.0M | 5.2M | |
| Property Plant And Equipment Gross | 769K | 577K | 993K | 1.9M | 1.9M | 1.9M | |
| Total Current Assets | 10.8M | 20.6M | 4.8M | 3.7M | 51.7M | 54.3M | |
| Accumulated Other Comprehensive Income | (2.0M) | (1.5M) | (1.2M) | (830K) | (892K) | (847.4K) | |
| Property Plant Equipment | 769K | 577K | 993K | 613K | 705.0K | 511.4K | |
| Net Tangible Assets | 10.2M | 20.0M | 2.9M | 202K | 181.8K | 172.7K | |
| Non Currrent Assets Other | (148K) | 194K | 160K | 122K | 87K | 61.7K | |
| Other Assets | 9K | 194K | 160K | 122K | 140.3K | 147.3K | |
| Non Current Liabilities Total | 213K | 1.1M | 559K | 284K | 38K | 36.1K | |
| Capital Lease Obligations | 405K | 213K | 811K | 559K | 284K | 249.9K | |
| Short Term Debt | 192K | 213K | 252K | 275K | 284K | 298.2K | |
| Short Long Term Debt Total | 405K | 213K | 811K | 559K | 284K | 277.7K | |
| Net Invested Capital | 10.2M | 20.0M | 2.9M | 202K | 47.2M | 49.6M | |
| Net Working Capital | 9.7M | 19.2M | 2.3M | (249K) | 46.8M | 49.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Benitec Biopharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Benitec Biopharma. If investors know Benitec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Benitec Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.51) | Revenue Per Share 0.003 | Quarterly Revenue Growth 0.125 | Return On Assets (0.50) | Return On Equity (0.92) |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Benitec Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Benitec Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Benitec Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.